Hepatoprotective potential of Saraca ashoka (Roxb.) De Wilde bark by carbon tetrachloride induced liver damage in rats  by Arora, Bharti et al.
Bulletin of Faculty of Pharmacy, Cairo University (2015) 53, 23–28HO ST E D  BY
Cairo University
Bulletin of Faculty of Pharmacy, Cairo University
www.elsevier.com/locate/bfopcu
www.sciencedirect.comORIGINAL ARTICLEHepatoprotective potential of Saraca ashoka
(Roxb.) De Wilde bark by carbon tetrachloride
induced liver damage in rats* Corresponding author.
E-mail address: manjushachoudhary@gmail.com (M. Choudhary).
Peer review under responsibility of Faculty of Pharmacy, Cairo
University.
http://dx.doi.org/10.1016/j.bfopcu.2014.11.002
1110-0931 ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.Bharti Arora a, Manjusha Choudhary a,*, Preeti Arya a, Sunil Kumar a,
Nitesh Choudhary b, Surender Singh ca Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra 136118, Haryana, India
b RP Inderprastha Insttitue of Technlogy, Karnal 132001, Haryana, India
c All India Institute of Pharmacology, New Delhi 110029, IndiaReceived 27 August 2014; accepted 13 November 2014
Available online 6 December 2014KEYWORDS
Hepatotoxicity;
Saraca ashoka;
Carbon tetrachloride;
HepatocytesAbstract Objective: Saraca ashoka [SA] (Family: Caesalpiniaceae) is widely used in skin infection,
CNS function, uterus pain during painful periods, in bacterial infection and for hepatoprotective
activity. The present study was carried out to investigate possible hepatoprotective activity of meth-
anolic and hydroalcoholic extract of Saraca ashoka stem bark.
Methods: Hepatoprotective activity of hydroalcoholic and methanolic extract of stem bark of S.
ashoka (HAESA and MESA) was demonstrated by using CCl4 induced hepatotoxicity model. Nor-
mal group was given only vehicle and CCl4 was given at 0.5 mL/kg, s.c. as toxic dose to induce hep-
atotoxicity. Liv-52 was given as standard drug (1 mL/kg/day, p.o.). Two doses of MESA and
HAESA (200 and 400 mg/kg/day, p.o.) were tested for hepatoprotective activity for nine days.
Results: Administration of hepatoxin CCl4 showed signiﬁcant biochemical and histological deteri-
oration in the liver of experimental animals. Pretreatment with methanolic extract more signiﬁ-
cantly and to a lesser extent hydroalcoholic extract reduced the elevated levels of serum enzymes
like serum glutamic-oxaloacetic transaminase (SGOT), serum glutamic-pyruvic transaminase
(SGPT) and alkaline phosphatase (ALP) and reversed the hepatic damage which evidenced the
hepatoprotective activity of stem bark of S. ashoka.
Conclusion: The results suggest that MESA and HAESA extracts at doses of 200 and 400 mg/kg,
p.o. have a signiﬁcant effect on the liver of CCl4 induced hepatotoxicity animal model.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
The liver plays a pivotal role in the regulation of vital physio-
logical functions such as metabolism, secretion of bile, storage
of vitamins and detoxiﬁcation of drugs.1 Liver diseases are
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world and can be classiﬁed as acute or chronic hepatitis and
cirrhosis. Hepatotoxicity implies chemical-driven liver damage
and can occur due to overdose and sometimes even in thera-
peutic ranges, may injure the organ. Other chemical agents,
such as those used in laboratories and industries can also
induce hepatotoxicity.2 Drug induced liver injury is responsible
for 5% of all hospital admissions and 50% of all acute liver
failures.3
In spite of tremendous strides in modern medicine, there
are very less drugs that stimulate liver function, offer protec-
tion to the liver from damage or help regeneration of hepa-
tocytes.4 Herbal drugs have gained importance and
popularity in recent years because of their safety, efﬁcacy
and cost effectiveness. Traditional medical systems such as
Ayurveda, Siddha and Unani are predominantly based on
the use of plant materials. Many formulations containing
herbal extracts are sold in the Indian market for liver disor-
ders. One such formulation is Liv-52 which is very com-
monly used as hepatotonic.5
Saraca ashoka is an evergreen plant belonging to family
caesalpiniaceae6,7 and found throughout India, especially
in Himalayas, Kerala, Bengal and whole South region.
The plant exhibit hepatoprotective, antibacterial and anti-
cancer activities8,9 as well as is used to treat skin infection,
CNS function, uterus pain during painful periods, clots and
ammenorhoea.10–12 Phytochemical study of the bark extract
showed the presence of phytosterols, carbohydrates, tannins
and glycosides.13 Glycosides (polyethanoid) are known to
possess anti-inﬂammatory, hepatoprotective and neuropro-
tective activities.14 In some of the plants of family caesal-
piniaceae biological activities such as anti-leukemic, anti-
inﬂammatory and hepatoprotective have been reported.
Some of the important plants under this family are Cae-
salpinia bonducella, Delonix regia, and Bauhinia racemosa.
Literature reviews indicated that the hepatoprotective activ-
ity of the bark of S. ashoka has not been scientiﬁcally eval-
uated so far. In view of this, the present study was aimed
at evaluating the hepatoprotective activity of the bark of S.
ashoka plant against CCl4 induced hepatotoxicity in albino
rats.
2. Materials and methods
2.1. Chemical reagent
Methanol and petroleum ether were purchased from SD Fine
Chemical Ltd. Carbon tetra chloride was obtained from Hime-
dia Laboratories Pvt. Ltd. and all biochemical estimation kits
were purchased from Erba diagnostic kits, Transasia biomed-
icals Ltd.
2.2. Plant material
The bark of S. ashoka was collected from Haryana Agriculture
University, Hisar district, Haryana and authenticated by Dr.
H.B Singh, Head, Raw Material Herbarium & Museum,
(RHMD), National Institute of Science Communication and
Information Resources, New Delhi, (India). Voucher specimen
Ref. No. NISCAIR/RHMD/CONSULT/-2010-11/1639/237
has been preserved there for future references.2.3. Preparation of plant extracts
The bark was washed under running tap water so as to remove
any type of contamination. Then washed plant material was
air dried under shade, powdered in grinder and passed through
the sieve of mesh size No. 40 The bark powder was ﬁrst defat-
ted by petroleum ether and then successive extraction was
done with methanol and hydroalcohol by the hot Soxhlet
extraction method. The extracts were ﬁltered and concentrated
by rotary evaporator under reduced pressure and preserved in
airtight container at 4–8 C for further investigation.
2.4. Preliminary phytochemical screening
Qualitative phytochemical investigation of MESA and
HAESA was carried out using standard procedure given by
Kokate and Harbone.15,16
2.5. Experimental animals
Wister albino rats (100–150 g) were purchased from the animal
house of Chaudhary Charan Singh Haryana Agriculture Uni-
versity, Hisar, Haryana (India). Animals were housed in ani-
mal house, Institute of Pharmaceutical Sciences, Kurukshetra
University, Kurukshetra, Haryana (India) and were fed with
available rat feed. The standard condition of temperature
(25 C± 5 C) humidity (55 ± 10%) and light/dark cycle
(12:12) was maintained properly. The study protocol was
approved by Institutional Animal Ethics Committee (IAEC)
(Register Number: 536/02/a/CPCSEA) and was conducted
according to the CPCSEA (Committee for the Purpose of
Control and Supervision of Experimental on Animals)
guidelines.
2.6. Selection of doses and administration
Doses of 200 and 400 mg/kg were selected based on the litera-
ture survey of previous research.17
2.7. Hepatoprotective activity
Hepatoprotective effect of MESA and HAESA extracts of
bark of S. ashoka was demonstrated by using the CCl4 induced
hepatotoxicity model and phenobarbitone induced sleeping
time. CCl4 activates by Cytochrome P-450 into a free radical
(CCl3) which causes peroxidative degradation in the adipose
tissue resulting in fatty inﬁlteration of the hepatocytes.18 Liver
toxicity also affects the metabolism of barbiturates thus
enhancing the sleeping time due to delay in excretion of pheno-
barbitone. So, the present study was aimed to investigate the
hepatoprotective activity of the bark of S. ashoka against
CCl4 induced hepatotoxicity in rats.
2.7.1. Carbon tetrachloride induced hepatotoxicity model
The effects of MESA and HAESA extracts were studied in
CCl4 induced hepatotoxicity. Wistar albino rats of either sex
weighing from 100 to 150 g were used in this method. Animals
were divided into seven groups containing six animals each. All
the groups were treated orally for 9 days. Rats in group I (nor-
mal control) received only distilled water (1 mL/kg, p.o.);
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(0.5 mL/kg, s.c.) for 9 days. Group III received standard drug
Liv-52 (1 mL/kg/day, p.o.) with CCl4 (0.5 mL/kg, s.c.) for
9 days. Group IV and V received MESA extract (200 and
400 mg/kg/day, p.o.) and CCl4 (0.5 mL/kg, s.c.) for 9 days;
group VI and VII received HAESA extract (200 and 400 mg/
kg/day, p.o.) and CCl4 (0.5 mL/kg, s.c.) for 9 days.
19 On the
10th day, all the animals were sacriﬁced under anesthesia
and blood as well as liver samples were collected for biochem-
ical and histopathological investigation.20,21
2.7.2. Phenobarbitone induced sleeping time
Liver toxicity affects the metabolism of barbiturates thus
enhancing the sleeping time due to delay in excretion of pheno-
barbitone. In this model, phenobarbitone sodium (40 mg/kg)
was administered after 48 h of last treatment of both the
extracts. The time interval between onset of sleep and regain
of righting reﬂex was measured.
2.7.3. Biochemical investigation
Blood samples were taken by retro orbital plexus and allowed
to clot at room temperature for 45 min. Centrifugation was
done at 1200–1500 rpm for 20 min for separation of serum.
The serum was used for the estimation of biochemical param-
eters namely serum glutamic-oxaloacetic transaminase
(SGOT), serum glutamic-pyruvic transaminase (SGPT) and
alkaline phosphatase (ALP) by using autoanalyzer.
2.7.4. Histopathology
After draining the blood, liver samples were excised and
washed with normal saline and processed separately for histo-
logical observations. Initially the samples were ﬁxed in 10%
buffered neutral formalin for 48 h and then with bovine solu-
tion for 6 h. Liver tissues were dehydrated with alcohol and
their parafﬁn section were cut in 5 mm thickness, and were
stained with alum hematoxylin and eosin.22 The sections were
examined microscopically for histopathological parameters at
Anupam Memorial Garg Diagnostic Center, Sirsa.
2.8. Statistical analysis
Statistical analysis was carried out by a one-way analysis of
variance (ANOVA) followed by Dunnett’s test. Results wereTable 1 Chemical constituents present in MESA and HAESA extr
S. No. Phytoconstituents Method
1 Alkaloids Dragendorﬀ’s test
Mayer’s test
Hager’s test
2 Carbohydrates Molish’s test
Fehling’s test
3 Steroids Liebermann–Burchard
4 Tannins Ferric chloride test
5 Saponins Foam test
6 Proteins and amino acids Millon’s test
Ninhydrin test
7 Flavonoids Shinoda test
Lead acetate test
+ indicates positive;  indicates negative.expressed as mean ± S.E.M for six rats in each group. p
value < 0.05 was considered signiﬁcant.
3. Results
3.1. Preliminary phytochemical screening
Preliminary screening revealed the presence of carbohydrates,
steriods, tannin, saponin, ﬂavonoids, protein and amino acids
in methanolic and hydroalcoholic extracts (Table 1).
3.2. Pharmacological evaluation
3.2.1. CCl4 induced hepatotoxicity
In CCl4 treated rats, the levels of SGOT, SGPT and ALP
increased as compared to the vehicle control group. Pretreat-
ment with Liv-52 reduced SGOT signiﬁcantly (p< 0.01) as
compared with diseased control. Both MESA and HAESA
extracts also decreased the SGOT signiﬁcantly (p< 0.01) at
both the doses but effect of MESA at dose 400 mg/kg was
superior to dose 200 mg/kg and comparable to the standard
group. MESA and HAESA extracts at the dose of 400 mg/
kg showed signiﬁcant changes (p< 0.01) and reduced the level
of SGPT and ALP (Table 2).
3.2.2. Phenobarbitone induced sleeping time
Due to hepatic injury, barbiturate metabolism is delayed and
excretion is slow. The CCl4 control group has prolonged sleep-
ing time when compared to the vehicle control group. MESA
extracts reduced the sleeping time (p< 0.05) at the dose of
400 mg/kg signiﬁcantly as compared to CCl4 induced hepato-
toxic group (Table 3).
3.3. Histopathological studies
Vehicle control group showed normal central vein and hepato-
cytes. CCl4 toxic group showed degeneration of hepatocytes
with fatty changes (Fig. 1). Liv-52 treated group showed nor-
mal central vein and mild changes in hepatocytes. MESA and
HAESA (200 mg/kg) treated animals showed normal hepato-
cytes and less or mild fatty changes. MESA and HAESA
(400 mg/kg) showed dilated vein and mild degenerate
hepatocytes.acts of S. ashoka.
Methanolic extract Hydroalcoholic extract
 
 
 
+ +
+ +
reaction + 
+ +
+ +
+ +
++ 
++ +
Table 3 Effect of pretreatment of Liv-52, MESA and HAESA extracts of S. ashoka on phenobarbotone induced sleeping time in CCl4
induced liver injury.
Groups Treatment Dose (mg/kg, p.o.) Duration of phenobarbitone induce sleep in min (% reduction)
Group 1 Vehicle Control – 278.78 ± 8.0*
Group 2 CCl4 Control – 339.02 ± 7.0
Group 3 CCl4 + Liv52 – 277.95 ± 3.0
*
Group 4 CCl4 +MESA 200 291.28 ± 15.4
Group 5 CCl4 +MESA 400 277.95 ± 14.8
*
Group 6 CCl4 + HASEA 200 304.61 ± 18.6
Group 7 CCl4 + HASEA 400 289.61 ± 17.6
Values were expressed as mean ± SEM (n= 6 rats/group). Percentage reduction in parameters compared to Liv-52 and difference between
CCl4 & Liv-52 treatment group
*(p< 0.05) (One-way ANOVA followed by Dunnett’s Test).
Table 2 Effect of MESA and HAESA extracts of S. ashoka on serum SGOT, SGPT and ALP in CCl4 induced liver toxicity.
Groups Treatment Dose (mg/kg, p.o.) SGOT(IU/L) SGPT(IU/L) ALP(IU/L) Liver weight (g)
Group 1 Vehicle control – 95.04 ± 3.3 37.41 ± 2.1 17.05 ± 0.8 2.98 ± 0.1
Group 2 CCl4 control – 189.43 ± 12.8 134.43 ± 8.2 100.53 ± 3.8 4.08 ± 0.1
Group 3 CCl4 + Liv 52 – 109.43 ± 5.8
** 47.13 ± 2.8** 35.04 ± 1.3** 3.09 ± 0.2**
Group 4 CCl4 +MESA 200 129.43 ± 9.1
** 75.03 ± 3.3** 62.76 ± 5.3** 3.02 ± 0.2**
Group 5 CCl4 +MESA 400 103.53 ± 7.8
** 43.46 ± 2.3** 39.66 ± 2.9** 3.60 ± 0.0
Group 6 CCl4 + HAESA 200 149.83 ± 5.9
** 73.63 ± 6.8** 70.03 ± 5.8** 3.54 ± 0.1
Group 7 CCl4 + HAESA 400 128.03 ± 8.3
** 48.74 ± 4.8** 44.87 ± 3.4** 4.15 ± 0.0
Values was mean ± S.E.M, n= 6 in each group, all groups were compared with disease control, *(p< 0.05), **(p< 0.01) (One way ANOVA
followed by Dunnett’s Test).
26 B. Arora et al.4. Discussion and conclusion
Liver diseases like hepatotoxicity remains as one of the serious
health problems and every year approximately 18,000 deaths
occur due to liver cirrhosis. It is considered to be one of the
most prevalent causes of human sufferings and death.23,24
Unfortunately synthetic drugs used in the treatment of liver
diseases are inadequate and sometimes can have serious side
effects.25
Herbs are one of the most promising sources of new drugs
as these are free of or having very less side effects and adverse
reactions. Various plant extracts and polyherbal formulations
play a speciﬁc therapeutically active role in the management of
liver disorder. Liv-52 is a polyherbal used traditionally in the
treatment of various liver disorders. It is a polyherbal formu-
lation consisting of powders of Capparis spinosa, Cichorium
intybus, Solanum nigrum, Cassia occidentalis, Terminalia
arjuna, Achillea millefolium, Tamarix gallica, and Mandura
bhasma.26 The hepatoprotective activity of esculetin and
p-methoxybenzoic acid, the main constituents of Cichorium
intybus and Capparis spinosa, respectively, has been reported
by previous researchers, in chemically-induced hepatotoxicity
in experimental animals.27–29 The hepatoprotective effects of
Mandura bhasma and Cassia occidentalis, and the other two
components of Liv-52 were also investigated against chemi-
cally-induced liver damage in experimental animals.30,31 Keep-
ing in view the above facts, Liv-52 was selected as standard.
The hepatoprotective effects of both MESA and HAESA
extracts of S. ashoka were studied in rats by using the CCl4
induced hepatotoxicity model at the doses of 200 and
400 mg/kg.
CCl4 is a potent hepatotoxin
32 activated by Cytochrome
P-450 into a free radical (CCl3) which causes peroxidativedegradation in the adipose tissue resulting in fatty inﬁlteration
of the hepatocytes. CCl3 radical further interacts with
molecular oxygen to form trichloromethyl peroxy radical.
Both CCl3 and peroxy radical are capable of binding to protein
or lipid which elicit lipid peroxidation leading to functional
and structural disruption of hepatocytes.33,34 During hepatic
damage, cellular enzymes like SGOT, SGPT and ALP will leak
into the serum resulting in elevation of their serum concentra-
tions. Hepatology of the damaged liver showed histological
changes, such as fatty changes in hepatocytes and perivenular
ﬁbrosis. We observed that pretreatment with Liv-52 and bark
extracts of S. ashoka showed a signiﬁcant protective effect
against CCl4 induced liver damage and signiﬁcantly reduced
the elevated liver enzymes indicating the hepatoprotective
action. Both the extracts of the bark of A. ashoka prevented
the histological changes caused by CCl4 which further
conﬁrmed its hepatoprotective activity against CCl4-induced
hepatic damage. The possible mechanism of action may be
associated with scavenging of free radicals responsible for
CCl4 toxicity.
In this investigation, we observed that there is marked liver
damage due to CCl4 intoxication with elevation in various
markers like SGOT, SGPT and ALP. Pretreatment with bark
extracts for 9 days and Liv-52 has signiﬁcantly reduced lipid
peroxidation and elevated biochemical markers.
These results showed that the treatment with MESA and
HAESA extracts of S. ashoka possessed signiﬁcant protection
against liver damage caused by CCl4. Hepatoprotective activ-
ity was conﬁrmed by the results of biochemical, and histolog-
ical studies. The hepatoprotective activity of S. ashoka may be
due to ﬂavonoids which were present in both the methanolic
and hydroalcoholic extracts. Flavonoids are known for their
powerful free radical scavenging activity.35 Superoxide anion
Group 1 (Vehicle group)                                          Group II (CCl4 intoxicated group) 
 Group III (Liv-52 +CCl4)                               Group IV (MESA 200 mg/kg+CCl4)        
Group V (MESA 400 mg/kg+CCl4)          Group VI (HAESA 200 mg/kg+CCl4) 
Group VII (HAESA 200 mg/kg+CCl4)
Figure 1 Histopathology of MESA and HAESA extracts of S. ashoka leaves on CCl4-induced hepatotoxicity in rats.
Hepatoprotective potential of Saraca ashoka 27and hydroxyl ion present in ﬂavonoids show antioxidant prop-
erty which effectively helps detoxify the toxic compounds.36
Thus these results showed that the extracts possess hepatopro-
tective activity.
Thus the result showed that the MESA and HAESA
extracts of S. ashoka have hepatoprotective activity against
CCl4 induced hepatotoxicity at both the doses of 200 and
400 mg/kg. The antioxidant property of phytoconstituents of
the bark of S. ashoka may be the possible mechanism for its
hepatoprotective activity.5. Conﬂict of interest statement
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